Komal Jhaveri MD, FACP

Dr. Komal Jhaveri is an Associate Attending Physician and serves as the Section Head for the Endocrine Therapy Research Program and as the Clinical Director for the Early Drug Development Service at MSKCC. She is an Associate Professor at Weill Cornell Medicine in NYC. After earning her medical degree and training in nuclear medicine from the University of Mumbai, she completed an Internal Medicine residency from the Icahn School of Medicine at Mount Sinai (Morningside/West) Program in NY and a Medical Oncology/Hematology fellowship at MSKCC. From 7/2012 to 5/2015, she served as an Assistant Professor at New York University and as an Attending Physician at the Langone Medical Center and at Bellevue Hospital.

Dr. Jhaveri’s primary research interests focus on the development of improved therapies for patients with breast cancer, with a focus on conducting novel clinical trials integrated with translational biomarker work. She has led the development of many targeted therapies including but not limited to PI3K/Akt inhibitors, FGFR inhibitors, ERBB2 inhibitors, oral SERDs, and Antibody-drug conjugates, amongst others.

Dr. Jhaveri currently serves as a member of the ASCO/TAPUR Molecular Tumor Board and as a member of the expert panel for ASCO’s guideline on the use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage breast cancer. She is a member of the Alliance Breast Committee and serves as the Co-Chair of the Endocrine Resistance working group within the Translational Breast Cancer Research Consortium. Her work has been presented at annual scientific meetings and she has been published widely in many reputable journals.